773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis
Authors: GIORGINO FRANCESCO , GUJA CRISTIAN , DAVIES MELANIE J. , AYDIN HASAN , LAUAND FELIPE , SOUHAMI ELISABETH , MELAS-MELT LYDIE , ARODA VANITA R. , ROSENSTOCK JULIO 
Published: June 2023

SGLT2i therapy is recommended for people with T2D, especially those at high cardiovascular risk or with chronic kidney disease or heart failure, due to its protective effects. This analysis evaluated glycemic and safety outcomes for iGlarLixi with or without existing SGLT2i therapy.
This exploratory analysis examined outcomes in people with T2D who were receiving an SGLT2i when initiating iGlarLixi (SGLT2i users) and those who were not (SGLT2i non-users) in a pooled dataset of LixiLan-G (people advancing therapy from a GLP-1 RA), and SoliMix and LixiLanOne CAN (people advancing from basal insulin).
Baseline characteristics were generally similar between SGLT2i users and non-users (Table). Least squares mean change (LSMC) (95% CI) from baseline to Week 26 in HbA1c was −1.2% (−1.4%, −1.1%) for users and −1.2% (−1.2%, −1.1%) for non-users. LSMCs in fasting/post-prandial glucose and body weight were similar in both groups. There was no increased risk of hypoglycemia in SGLT2i users. Gastrointestinal adverse events were comparable between groups.
Concomitant SGLT2i and iGlarLixi therapy provides improvements in glycemic control with low hypoglycemia and gastrointestinal adverse event rates, as demonstrated in trials with different populations and study designs in people with T2D.

Disclosure
F.Giorgino: Advisory Panel; Boehringer-Ingelheim, Amarin Corporation, Medtronic, Roche Diabetes Care, Sanofi, Bayer Inc., Novo Nordisk, Consultant; Novo Nordisk, Lilly, Research Support; Lilly, Roche Diabetes Care, AlfaSigma, Speaker's Bureau; Abbott, Boehringer-Ingelheim, Lilly, Sanofi, Medscape. C.Guja: Advisory Panel; AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Speaker's Bureau; AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Servier Laboratories, Viatris Inc. M.J.Davies: Advisory Panel; Lilly, Boehringer-Ingelheim, Novo Nordisk, Sanofi, Lexicon Pharmaceuticals, Inc., Pfizer Inc., Medtronic, ShouTi Pharma Inc., Consultant; Lilly, Boehringer-Ingelheim, Novo Nordisk, Sanofi, Research Support; AstraZeneca, Novo Nordisk, Sanofi-Aventis U.S., Boehringer-Ingelheim, Janssen Pharmaceuticals, Inc., Speaker's Bureau; Lilly, Boehringer-Ingelheim, Novo Nordisk, AstraZeneca, Napp Pharmaceuticals Limited, Novartis, Sanofi. H.Aydin: Advisory Panel; Sanofi, Novo Nordisk, Boehringer Ingelheim Inc., Speaker's Bureau; Novo Nordisk. F.Lauand: Employee; Sanofi. E.Souhami: Employee; Sanofi, Stock/Shareholder; Sanofi. L.Melas-melt: None. V.R.Aroda: Consultant; Applied Therapeutics Inc., Fractyl Health, Inc., Novo Nordisk, Pfizer Inc., Sanofi, Other Relationship; Janssen Pharmaceuticals, Inc., Research Support; Applied Therapeutics Inc., Eli Lilly and Company, Fractyl Health, Inc., Novo Nordisk, Sanofi. J.Rosenstock: Advisory Panel; Applied Therapeutics Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Novo Nordisk, Oramed Pharmaceuticals, Sanofi, Zealand Pharma A/S, Intarcia Therapeutics, Inc., Hanmi Pharm. Co., Ltd., Research Support; Applied Therapeutics Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis, Novo Nordisk, Pfizer Inc., Sanofi, Intarcia Therapeutics, Inc.

Funding
Sanofi